A novel study using a mouse model has found that the absence of the angiopoietin-like 4 (ANGPTL4) protein during development ...

“Our platform is designed to reprogram the immune system, restoring tolerance without the burden of chronic immunosuppression. By combining DNA instructions with our proprietary delivery platform, we ...

When food is scarce, stress hormones direct the immune system to operate in "low power" mode to preserve immune function while conserving energy, according to researchers at Weill Cornell Medicine.

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the "recipe" for the transformation. Researchers at Lund University have now created ...

I attended the Global Wellness Summit in Dubai (my 13th consecutive, I think), which focused on transformative technologies that are making wellness for an extended lifetime more attainable. The use ...

For millions of people around the world, asthma is more than just a breathing problem — it is a chronic and often debilitating condition caused by the immune system's exaggerated response to harmless ...

When the immune system is imbalanced, either due to overly-active cells or cells that suppress its function, it causes a wide range of diseases, from psoriasis to cancer. By manipulating the function ...

Studies have shown that cancer cells can 'trick' the immune system into believing they are healthy and prevent themselves ...

Amyotrophic lateral sclerosis (ALS) is marked by relentless motor neuron loss, but the disease also comes with a deeper immune imbalance. At the heart of this dysregulation is a breakdown in ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on ...

When food is scarce, stress hormones direct the immune system to operate in "low power" mode to preserve immune function while conserving energy ...

Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...